Lansoprazol Krka

Lansoprazole, the active ingredient in Lansoprazol Krka, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid production and is used to treat conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease, erosive esophagitis and as part of Helicobacter pylori eradication therapy.

GNH USA supplies Lansoprazol Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazol Krka acts on the gastric proton pump to lower acid secretion, benefiting several acid‑related disorders. - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and esophageal irritation. - Peptic ulcer disease: promotes ulcer healing and prevents recurrence. - Erosive esophagitis: reduces mucosal damage and supports recovery. - Helicobacter pylori eradication: used in combination therapy to increase eradication rates.

Adverse reactions may occur with Lansoprazol Krka use.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools occurring intermittently. - Nausea: feeling of stomach upset. - Abdominal pain: discomfort in the upper abdomen. - Flatulence: increased gas production. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): swelling, difficulty breathing. - Clostridium difficile infection: severe colitis with watery diarrhea. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Liver inflammation (hepatitis): jaundice, elevated liver enzymes. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: extensive skin blistering. - Severe skin rash: widespread erythema and itching.

Before initiating therapy, consider the following precautions. - Assess renal function: adjust use in severe renal impairment. - Monitor magnesium levels: long‑term therapy may cause deficiency. - Avoid abrupt discontinuation: risk of rebound acid hypersecretion. - Use with caution in elderly patients: higher incidence of adverse events. - Store at room temperature: keep in the original pack, protect from moisture.

Lansoprazol Krka may interact with several medicines.

Major Interactions (Avoid): - Ketoconazole: reduced absorption and efficacy. - Atazanavir: decreased antiviral effectiveness. - Clopidogrel: reduced activation leading to diminished antiplatelet effect.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum concentrations. - Warfarin: enhanced anticoagulant effect, risk of bleeding. - Methotrexate: increased toxicity, especially at high doses.